Ellis Investment Partners’s AstraZeneca AZN Stock Holding History

Ellis Investment Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-754	Closed	-$82K	–	243
2022 Q3	$82K	Buy	754 +6	+0.8%	+$761	0.02%	319
2022 Q2	$98K	Sell	748 -22	-3%	-$2.89K	0.03%	306
2022 Q1	$102K	Sell	770 -26	-3%	-$3.12K	0.02%	313
2021 Q4	$92K	Buy	796 +458	+136%	+$53.9K	0.02%	333
2021 Q3	$40K	Buy	338 +2	+0.6%	+$233	0.01%	424
2021 Q2	$40K	Sell	336 -1	-0.3%	-$110	0.01%	427
2021 Q1	$33K	Sell	337 -149	-31%	-$15K	0.01%	440
2020 Q4	$49K	Hold	486	–	–	0.01%	376
2020 Q3	$53K	Buy	486 +4	+0.8%	+$445	0.02%	357
2020 Q2	$51K	Buy	482 +190	+65%	+$19.6K	0.02%	356
2020 Q1	$25K	Buy	292 +46	+19%	+$4.33K	0.01%	376
2019 Q4	$24K	Hold	246	–	–	0.01%	421
2019 Q3	$21K	Buy	246 +3	+1%	+$260	0.01%	436
2019 Q2	$20K	Buy	+243	New	+$19.1K	0.01%	440

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ellis Investment Partners's AZN Position: Q4 2022 in Review

Ellis Investment Partners sold out of AstraZeneca (AZN) in Q4 2022, closing a stake of 754 shares — an estimated $82K sold.

Ellis Investment Partners first reported a position in AZN in Q2 2019 and held it in 14 quarters. The position peaked at $102K in Q1 2022. 1,061 funds tracked by Wall St. Rank hold AZN as of Q4 2022.

Ellis Investment Partners reported no remaining AstraZeneca position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 754 AstraZeneca shares in Q4 2022, an estimated $82K.
Ellis Investment Partners first reported a position in AstraZeneca in Q2 2019 and held it in 14 quarters.
Ellis Investment Partners's AstraZeneca position peaked at $102K in Q1 2022.
1,061 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.